Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma

Journal of Hematology & Oncology

Wei Li Zhao¹  Sai Juan Chen¹  Zhi Xiang Shen²  Yang Shen²  Li Wang¹  Zhong Zheng²  Shu Cheng²  Li Hua Dong² 

[1] Pôle de Recherches Sino-Français en Science du Vivant et Génomique, Laboratory of Molecular Pathology, Shanghai, China;State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

关键词: MYC;    Burkitt leukemia/lymphoma;    Autophagy;    MTOR inhibitor;    Histone deacetylase inhibitor;   

Others  :  804427
DOI  :  10.1186/1756-8722-6-53

 received in 2013-05-13, accepted in 2013-07-14,  发布年份 2013

【 摘 要 】

Background

Burkitt leukemia/lymphoma is a major subtype of aggressive B-cell lymphoma. Biological targeted therapies on this disease need to be further investigated and may help to improve the clinical outcome of the patients.

Methods

This study examined the anti-tumor activity of the histone deacetylases (HDAC) inhibitor valproic acid (VPA) combined with the mammalian target of rapamycin (MTOR) inhibitor temsirolimus in Burkitt leukemia/lymphoma cell lines, as well as in primary tumor cells and a murine xenograft model.

Results

Co-treatment of VPA and temsirolimus synergistically inhibited the tumor cell growth and triggered the autophagic cell death, with a significant inhibition of MTOR signaling and MYC oncoprotein. Functioned as a class I HDAC inhibitor, VPA potentiated the effect of temsirolimus on autophagy through inhibiting HDAC1. Molecular silencing of HDAC1 using small interfering RNA (siRNA) attenuated VPA-mediated regulation of CDKN1A, CDKN1B and LC3-I/II, regression of tumor cell growth and induction of autophagy. Meanwhile, VPA counteracted temsirolimus-induced AKT activation via HDAC3 inhibition. HDAC3 siRNA abrogated the ability of VPA to modulate AKT phosphorylation, to suppress tumor cell growth and to induce autophagy. Strong antitumor effect was also observed on primary tumor cells while sparing normal hematopoiesis ex vivo. In a murine xenograft model established with subcutaneous injection of Namalwa cells, dual treatment efficiently blocked tumor growth, inhibited MYC and induced in situ autophagy.

Conclusions

These findings confirmed the synergistic effect of the HDAC and MTOR inhibitors on Burkitt leukemia/lymphoma, and provided an insight into clinical application of targeting autophagy in treating MYC-associated lymphoid malignancies.

【 授权许可】

   
2013 Dong et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Sander S, Calado DP, Srinivasan L, Kochert K, Zhang B, Rosolowski M, Rodig SJ, Holzmann K, Stilgenbauer S, Siebert R, et al.: Synergy between PI3K Signaling and MYC in Burkitt Lymphomagenesis. Cancer Cell 2012, 22(2):167-179.
• [2]Blum KA, Lozanski G, Byrd JC: Adult Burkitt leukemia and lymphoma. Blood 2004, 104(10):3009-3020.
• [3]Dalby KN, Tekedereli I, Lopez-Berestein G, Ozpolat B: Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer. Autophagy 2010, 6(3):322-329.
• [4]Mizushima N, Levine B, Cuervo AM, Klionsky DJ: Autophagy fights disease through cellular self-digestion. Nature 2008, 451(7182):1069-1075.
• [5]Qu X, Yu J, Bhagat G, Furuya N, Hibshoosh H, Troxel A, Rosen J, Eskelinen EL, Mizushima N, Ohsumi Y, et al.: Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest 2003, 112(12):1809-1820.
• [6]Huang JJ, Zhu YJ, Lin TY, Jiang WQ, Huang HQ, Li ZM: Beclin 1 expression predicts favorable clinical outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP. Hum Pathol 2011, 42(10):1459-1466.
• [7]Huang JJ, Li HR, Huang Y, Jiang WQ, Xu RH, Huang HQ, Lv Y, Xia ZJ, Zhu XF, Lin TY, et al.: Beclin 1 expression: a predictor of prognosis in patients with extranodal natural killer T-cell lymphoma, nasal type. Autophagy 2010, 6(6):777-783.
• [8]Johnston PB, Yuan R, Cavalli F, Witzig TE: Targeted therapy in lymphoma. J Hematol Oncol 2010, 3:45. BioMed Central Full Text
• [9]Zoncu R, Efeyan A, Sabatini DM: mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011, 12(1):21-35.
• [10]Witzig TE, Gupta M: Signal transduction inhibitor therapy for lymphoma. Hematology Am Soc Hematol Educ Program 2010, 2010:265-270.
• [11]Yuan R, Kay A, Berg WJ, Lebwohl D: Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol 2009, 2:45. BioMed Central Full Text
• [12]Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK: Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001, 1(3):194-202.
• [13]Cang S, Ma Y, Liu D: New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer. J Hematol Oncol 2009, 2:22. BioMed Central Full Text
• [14]Sakajiri S, Kumagai T, Kawamata N, Saitoh T, Said JW, Koeffler HP: Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Exp Hematol 2005, 33(1):53-61.
• [15]Zain J, Rotter A, Weiss L, Forman S, Kirschbaum MH: Valproic acid monotherapy leads to CR in a patient with refractory diffuse large B cell lymphoma. Leuk Lymphoma 2007, 48(6):1216-1218.
• [16]Bjorkoy G, Lamark T, Brech A, Outzen H, Perander M, Overvatn A, Stenmark H, Johansen T: p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. J Cell Biol 2005, 171(4):603-614.
• [17]Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
• [18]Reeder CB, Ansell SM: Novel therapeutic agents for B-cell lymphoma: developing rational combinations. Blood 2011, 117(5):1453-1462.
• [19]Catalano MG, Fortunati N, Pugliese M, Costantino L, Poli R, Bosco O, Boccuzzi G: Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells. J Clin Endocrinol Metab 2005, 90(3):1383-1389.
• [20]Raymond E, Alexandre J, Faivre S, Vera K, Materman E, Boni J, Leister C, Korth-Bradley J, Hanauske A, Armand JP: Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004, 22(12):2336-2347.
• [21]Coulter DW, Walko C, Patel J, Moats-Staats BM, McFadden A, Smith SV, Khan WA, Bridges AS, Deal AM, Oesterheld J, Davis IJ, Blatt J: Valproic acid reduces the tolerability of temsirolimus in children and adolescents with solid tumors. Anticancer Drugs 2013, 24(4):415-421.
• [22]Cloonan SM, Williams DC: The antidepressants maprotiline and fluoxetine induce Type II autophagic cell death in drug-resistant Burkitt's lymphoma. Int J Cancer 2011, 128(7):1712-1723.
• [23]Turzanski J, Daniels I, Haynes AP: Involvement of macroautophagy in the caspase-independent killing of Burkitt lymphoma cell lines by rituximab. Br J Haematol 2009, 145(1):137-140.
• [24]Yazbeck VY, Buglio D, Georgakis GV, Li Y, Iwado E, Romaguera JE, Kondo S, Younes A: Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma. Exp Hematol 2008, 36(4):443-450.
• [25]Fu J, Shao CJ, Chen FR, Ng HK, Chen ZP: Autophagy induced by valproic acid is associated with oxidative stress in glioma cell lines. Neuro Oncol 2010, 12(4):328-340.
• [26]Francisco R, Perez-Perarnau A, Cortes C, Gil J, Tauler A, Ambrosio S: Histone deacetylase inhibition induces apoptosis and autophagy in human neuroblastoma cells. Cancer Lett 2012, 318(1):42-52.
• [27]Xie HJ, Noh JH, Kim JK, Jung KH, Eun JW, Bae HJ, Kim MG, Chang YG, Lee JY, Park H, et al.: HDAC1 inactivation induces mitotic defect and caspase-independent autophagic cell death in liver cancer. PLoS One 2012, 7(4):e34265.
• [28]Gupta M, Ansell SM, Novak AJ, Kumar S, Kaufmann SH, Witzig TE: Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2. Blood 2009, 114(14):2926-2935.
• [29]Liu YL, Yang PM, Shun CT, Wu MS, Weng JR, Chen CC: Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma. Autophagy 2010, 6(8):1057-1065.
• [30]Memmott RM, Dennis PA: Akt-dependent and -independent mechanisms of mTOR regulation in cancer. Cell Signal 2009, 21(5):656-664.
• [31]Gustafson WC, Weiss WA: Myc proteins as therapeutic targets. Oncogene 2010, 29(9):1249-1259.
• [32]Balakumaran BS, Porrello A, Hsu DS, Glover W, Foye A, Leung JY, Sullivan BA, Hahn WC, Loda M, Febbo PG: MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagy. Cancer Res 2009, 69(19):7803-7810.
• [33]Kluk MJ, Chapuy B, Sinha P, Roy A, Dal Cin P, Neuberg DS, Monti S, Pinkus GS, Shipp MA, Rodig SJ: Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas. PLoS One 2012, 7(4):e33813.
• [34]Zhang QL, Wang L, Zhang YW, Jiang XX, Yang F, Wu WL, Janin A, Chen Z, Shen ZX, Chen SJ, et al.: The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis. Leukemia 2009, 23(8):1507-1514.